In September 2017, a class-action lawsuit
was filed against Pfizer for allegedly misleadingly marketing Maximum Strength Robitussin Cough+Chest Congestion DM to make consumers believe that the maximum strength product contains more of the active ingredients than the regular strength product when, according to the plaintiffs, the two products contain the same amount of one of the active ingredients (expectorant) and the regular strength products contains more of the other active ingredient (cough suppressant). (Haj et al v. Pfizer Inc.
, Case No. 17-cv-6730, N. D. IL.)
For more information about other class-action lawsuits regarding cough medicines and TINA.org’s coverage of the products, click here.